- Home
- / Iterum Therapeutics
Iterum Therapeutics
Stock Price
$1.5
2024-10-29
Market Capitalization
$32.9 M
2024-10-29
Iterum Therapeutics Summary
Company Summary
- Overview
- Iterum Therapeutics is a clinical-stage pharmaceutical company which aims to treat serious infections resulting from multi-drug resistant bacteria. It is engaged in developing differentiated anti-infectives. The Company offers an oral and intravenous antibiotic for the treatment of Gram-negative multi-drug resistant infections.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Dublin, IE | view all locations
- Website
- http://www.iterumtx.com/
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Ronald M. Hunt, Chairman
Michael Dunne, Director
Judith M. Matthews, Chief Financial Officer
LocationsView all
3 locations detected
Dublin HQ
Ireland
4th Floor, Block 2, Harcourt Centre, Harcourt Street, Dublin 2
Chicago, IL
United States
200 South Wacker Drive, 200 S Wacker Dr #2550
Old Saybrook, CT
United States
20 Research Pkwy
Iterum Therapeutics Financials
Summary Financials
- Revenue (Q3, 2025)
- $390.0K
- Gross profit (Q3, 2025)
- $1.1M
- Net income (Q3, 2025)
- ($9.0M)
- Cash (Q3, 2025)
- $11.0M
- EBIT (Q3, 2025)
- ($7.7M)
- Enterprise value
- $55.7M